TheraRadar
Data updated: Jun 28, 2026

DEUTETRABENAZINE · Aurobindo Pharma

CNS Approved 2017-04-03

DEUTETRABENAZINE is FDA-approved to treat 3 conditions (same as AUSTEDO).

Source: FDA Label
1
Indication
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2017-04-03
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: DEUTETRABENAZINE

DEUTETRABENAZINE Approval History

2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2024 to 2026
May 2026 SUPPL
Label · Labeling
Dec 2024 ORIGINAL
Update

What DEUTETRABENAZINE Treats

3 indications

DEUTETRABENAZINE is approved for 3 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Chorea
  • Huntington's Disease
  • Tardive Dyskinesia

Same approved indications as AUSTEDO (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT04713982 200069 Ph 2, Ph 3 active not recruiting Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
NCT07601516 TV50717-NDG-40182 Ph 4 completed Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEUTETRABENAZINE FDA Label Details

Indications & Usage

DEUTETRABENAZINE is FDA-approved to treat 3 conditions — same approved indications as AUSTEDO.

Looking for the branded version?

AUSTEDO

Full clinical data, patents, trials, and competitive landscape for deutetrabenazine.

See AUSTEDO

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.